Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions

@article{Fischer2006TreatmentFH,
  title={Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions},
  author={Benedikt Fischer and Jens Reimer and Michelle Firestone and Kate Kalousek and J{\"u}ergen Rehm and Jenny E. Heathcote},
  journal={European Journal of Gastroenterology \& Hepatology},
  year={2006},
  volume={18},
  pages={1039-1042}
}
Illicit drug users are the primary risk group for HCV transmission, and will form the largest HCV treatment population for years to come. Sylvestre et al. 's study suggests that cannabis use may benefit treatment retention and outcomes in illicit drug users undergoing HCV treatment. In fact, there is substantial evidence that cannabis use may help address key challenges faced by drug users in HCV treatment (e.g., nausea, depression), especially when such treatment occurs in the context of… Expand
HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study)
In Western countries, tobacco smoking is highly prevalent among patients co-infected with HIV and hepatitis C virus (HCV). In the era of antiretrovirals and HCV cure, smoking-related health damagesExpand
Problematic Cannabis Use and Risk of Complications in Patients with Chronic Hepatitis C
TLDR
CUD is significantly associated with 122% increased likelihood for hepatic encephalopathy that may worsen overall hospitalization outcomes in CHC patients and need to consider the complex relationship between CUD and CHC and manage them optimally to improve the health-related quality of life. Expand
Health Effects of Using Cannabis for Therapeutic Purposes: A Gender Analysis of Users’ Perspectives
TLDR
Although the reports of women and men were similar in many respects, there were important differences in patterns and practices of use that reflected gender influences and provide direction for developing gender-specific information to support decision making and usage for therapeutic users. Expand
Criminal Policy of Netherlands and U.S.A on Decriminalization of Soft Drugs
Background and Aim : Soft drugs are those drugs are very weak in terms of addiction and the effects are highly treatable. The challenging issue regarding this type of drugs is decriminalization ofExpand
International Journal of Social Science Research and Review
Drug decriminalization calls for reduced control and penalties compared to existing laws. Proponents of drug decriminalization generally support the use of fines or other punishments to replaceExpand
Medical Marijuana: The Conflict Between Scientific Evidence and Political Ideology. Part Two of Two
  • P. J. Cohen
  • Medicine
  • Journal of pain & palliative care pharmacotherapy
  • 2009
TLDR
It is concluded that political advocacy is a poor substitute for dispassionate analysis and that neither popular votes nor congressional “findings” should be permitted to trump scientific evidence in deciding whether or not marijuana is an appropriate pharmaceutical agent to use in modern medical practice. Expand
Controlling illegal stimulants: a regulated market model
  • M. Haden
  • Medicine, Psychology
  • Harm reduction journal
  • 2008
TLDR
This paper explores a proposal for a post-prohibition, public health based model for the regulation of the most problematic drugs, the smokable and injectable stimulants. Expand

References

SHOWING 1-10 OF 58 REFERENCES
Hepatitis C, illicit drug use and public health: does Canada really have a viable plan?
TLDR
Canada needs to reconsider the scope, delivery and resourcing of both preventive and treatment interventions targeting the primary risk population of illicit drug users to reduce the HCV disease burden. Expand
Injection drug use and the hepatitis C virus: Considerations for a targeted treatment approach-The case study of Canada
TLDR
It is concluded that treatment of HCV-infected illicit drug users is both feasible and may be necessary to reduce transmission and adverse outcomes in this high-risk population. Expand
Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.
  • B. Edlin, T. Kresina, +5 authors V. Cargill
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2005
TLDR
Elements of care for hepatitis C in illicit drug users include prevention counseling and education, testing for HCV and human immunodeficiency virus infection, vaccination against hepatitis A and B viruses, evaluation for comorbidities, coordination of substance-abuse treatment services, psychiatric care, and social support. Expand
Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.
TLDR
A pilot program to integrate care for HCV infection with substance abuse treatment in a setting of maintenance treatment with methadone is described, leading to high levels of adherence, with liver biopsy and substantial rates of initiation of antiviral therapy. Expand
Cannabis use improves retention and virological outcomes in patients treated for hepatitis C
TLDR
It is suggested that modest cannabis use may offer symptomatic and virological benefit to some patients undergoing HCV treatment by helping them maintain adherence to the challenging medication regimen. Expand
Illicit opioid use in Canada: Comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study)
TLDR
Overall, the majority of OPICAN participants regularly used both a variety of illicit opioids and cocaine or crack, reported physical and mental health problems, lacked permanent housing, were involved in crime, and had their “ideal” treatment not available to them. Expand
Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment.
TLDR
Screening and early treatment of IDUs could play an important role in controlling HCV infection and the rate of reinfection may not as high as supposed. Expand
Follow-up studies of treatment for hepatitis C virus infection among injection drug users.
  • O. Dalgard
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2005
TLDR
Several cases of probable reinfection in IDUs, 2 of which occurred during or after successful treatment for HCV infection are discussed, suggesting that the rate of long-term response to treatment forHCV infection is excellent inIDUs. Expand
Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups
TLDR
Data do not confirm the supposed increased risk for IFN‐α–induced mental side effects and dropouts in psychiatric patients if interdisciplinary care and antidepressant treatment are available, and preexisting psychiatric disorders or present methadone substitution should no longer be regarded as contraindications to treatment of chronic hepatitis C with IFN-α and ribavirin in an interdisciplinary setting. Expand
Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C
TLDR
Daily cannabis smoking is significantly associated with fibrosis progression during chronic hepatitis C (CHC), and patients with ongoing CHC should be advised to refrain from regular cannabis use. Expand
...
1
2
3
4
5
...